GT Medical Technologies Announces New Center of Excellence
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure
TEMPE, Ariz. / -- GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced UC San Diego Health Department of Neurological Surgery as the latest GammaTile Center of Excellence Program designation.
The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated exceptional expertise in the GammaTile procedure by meeting specific clinical criteria and annual case minimums, as well as ongoing education requirements.
Recognized Physicians
The following physicians have been acknowledged for their remarkable achievements:
- Dr. Mark Schwartz, Neurosurgery
- Dr. Jeff Steinberg, Neurosurgery
- Dr. Arjun Khanna, Neurosurgery
- Dr. Parag Sanghvi, Radiation Oncology
- Dr. Jona Hattangadi-Gluth, Radiation Oncology
- Dr. Alexander Khalessi, Neurosurgery
- Dr. David Piccioni, Neuro-oncology
- Dr. Thomas Beaumont, Neurosurgical Oncology
Innovative Treatment with GammaTile
GammaTile is an innovative form of radiation therapy placed during tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. This method significantly minimizes the treatment gap seen in traditional approaches where a delay between surgery and radiation is needed for wound healing.
With GammaTile, immediate localized radiation is applied directly at the tumor site to enhance treatment effectiveness against remaining cancer cells and to reduce the risk of regrowth. This revolutionary approach is allowing for transformative advancements in brain tumor care.
About GT Medical Technologies
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.
About GammaTile
GammaTile is an FDA-cleared, biodegradable collagen implant embedded with radiation seeds, specifically designed for patients with operable brain tumors. By providing radiation directly from within, placed into the surgical cavity at the time of tumor removal, GammaTile allows for immediate, localized treatment. This strategy targets residual cancer cells at their most vulnerable stage, which helps to prevent regrowth and minimizes exposure to healthy brain tissue.
Since its launch in the United States, GammaTile has been adopted by over 100 leading healthcare centers, demonstrating its wide acceptance and implementation in both academic and community settings. For more information, visit gammatile.com.
Frequently Asked Questions
What is the GammaTile Center of Excellence Program?
The GammaTile Center of Excellence Program recognizes institutions and physicians who are dedicated to advancing patient care in brain tumor treatment with exceptional skill and commitment to education.
What makes GammaTile innovative in brain tumor treatment?
GammaTile allows for immediate targeted radiation delivery during surgery, helping to reduce treatment gaps and improve outcomes for patients by targeting cancer cells right after tumor removal.
What criteria must physicians meet to be recognized?
Physicians must meet specific clinical criteria, maintain annual case minimums, and participate in ongoing education to qualify for the GammaTile Center of Excellence designation.
How has GammaTile been received by medical institutions?
Since its launch, GammaTile has been adopted by more than 100 leading medical centers, reflecting its growing acceptance in diverse healthcare environments.
What is the future of GammaTile in treatment?
With ongoing advancements and increased recognition, GammaTile is expected to further enhance the standard of care in brain tumor treatment and improve patient outcomes.
